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Abstract Clinical presentation of the chronic, heritable condition cystic fibrosis (CF) is complex, with a
diverse range of symptoms often affecting multiple
organs with varying severity. The primary source of
morbidity and mortality is due to progressive destruction of the airways attributable to chronic inflammation
arising from microbial colonisation. Antimicrobial
therapy combined with practises to remove obstructive
mucopurulent deposits form the cornerstone of current
therapy. However, new treatment options are emerging
which offer, for the first time, the opportunity to effect
remission from the underlying cause of CF. Here, we
discuss these therapies, their mechanisms of action, and
their successes and failures in order to illustrate the shift
in the nature of how CF will likely be managed into the
future.

1 Common and Characteristic Pathologies
Associated with Cystic Fibrosis (CF)
Cystic fibrosis (CF) is a heritable, chronic condition
affecting multiple organs. The loss of or reduction in
function of the CF transmembrane regulator (CFTR), a
transmembrane ion channel through which chloride and
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bicarbonate secretion are regulated, interferes with the
normal functioning of the epithelia within which it resides.
Functional CFTR is required to adequately hydrate the
airway surface liquid (ASL), the continuous transit of
which from the respiratory tract into the gastrointestinal
tract under ciliary movement aids in the preservation of
lung health and removal of inhaled microorganisms and
particles. People with CF, however, are unable to clear
their dehydrated airway mucous secretions, the prolonged
residence of which creates a niche that can be exploited by
a number of microorganisms. Many such colonising
microorganisms fail to be cleared by the immune system
and may persist for many years. Accordingly, this propagates a continuous inflammatory state in the airway which
causes bronchiectasis, a progressive destruction of lung
tissue architecture. Morbidity of the pulmonary epithelium
is most directly responsible for the decreased lifespan
experienced by people with CF. Ultimately, mortality
results from asphyxiation due to progressive destruction of
lung tissue caused by chronic infection and a chronic
inflammatory response. Pulmonary insufficiency is the
hallmark of CF clinical presentation, and this is reflected
by the common use of the FEV1 (forced airway expiratory
volume in 1 s) test as an outcome for efficacy of interventions during clinical trials for CF.
In addition to the airway, pathologies are frequently
associated with each of the intestinal, biliary and pancreatic
mucosa. In the pancreas, CFTR is localised to the apical
surface of pancreatic duct cells [1], where it serves to
secrete bicarbonate [2], which facilitates raising of the
duodenal pH by pancreatic fluid secretions. CFTR deficiency impairs the adequate exocrine functioning of the
pancreas [3], reducing fluid throughput, which serves to
concentrate secreted digestive enzymes. This, in turn, leads
to ductal occlusion and, hence, pancreatic insufficiency [4].
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This leads to pancreatic fibrosis with consequent intestinal
malabsorption of nutrients, for which therapeutic supplementation of digestive enzymes is required. Approximately
85 % of people with CF have pancreatic insufficiency [4],
with 87.3 % of patients in the USA requiring pancreatic
enzyme replacement therapy (PERT) in 2014 [5].
In addition to mediating compromised digestion,
defective CFTR mediates further pathology through the
pancreas: up to 50 % of people diagnosed with CF may
suffer from CF-related diabetes (CFRD). CFRD presents
atypically with respect to types 1 or 2 diabetes mellitus in
non-CF individuals [6], likely due to ancillary nutritional
deficiencies, and this can influence the diagnosis, with the
prevalence of the condition being approximately 6 % in
paediatric patients but rising to *50 % in adults [7].
Glucose-stimulated electrical conductance has long been
known to be involved in insulin secretion from pancreatic
b cells [8] and, given that CFTR is expressed on the surface of b cells [9], the absence of CFTR has recently been
proposed to result in dysregulation of glucose-mediated
electrical activity, hence preventing insulin secretion from
pancreatic b cells in some people with CF [10].
Disease of the liver is also a notable contributor to the
overall pathology of CF. Epidemiological estimates of its
prevalence vary, with incidences of 2–41 % or more having been reported from different studies [11–15]. CFTR in
the liver is localised to the luminal surface of intrahepatic
cholangiocytes of bile canaliculi [16], where it infuses
biliary secretions with bicarbonate in parallel to its function
in the pancreas, also serving to induce the efflux of bile
acids [17]. Thus, the absence of bicarbonate secretion
causes the retention of harmful bile acids within hepatocytes, inducing an inflammatory response, leading to
fibrosis analogous to that seen in the pancreas and, ultimately, cirrhosis and portal hypertension [18].
The morbidities associated with pancreatic and hepatic
insufficiency can, in turn, cause a number of gastrointestinal sequelae [19], leading to a complex clinical presentation of people with moderate or severe disease
requiring multiple concurrent treatment and management
strategies. Indeed, several co-morbidities, such as pancreatic insufficiency and CFRD, correlate with lesser lung
function [20].
These morbidities and their ensuing therapies can have
adverse secondary effects when administered routinely for
chronic illness, with secondary kidney dysfunction being
an example of this. The kidney can be damaged by successive rounds of non-steroidal anti-inflammatories,
aminoglycoside antibacterials, as well as chronic infection
itself, or CFRD and insulin treatment [21].
Each of these primary morbidities may individually or
interactively engender a number of potential acute or
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chronic sequelae themselves requiring management for
patients [22].

2 Treatment Strategies
Myriad treatments are prescribed to address the complications engendered by the loss of CFTR function. The
majority of these abate the symptoms of this loss but
cannot restore the function of the proteins. As our understanding of the structure of native CFTR and its CF-causing mutants has improved, alongside the attendant
functional consequences of these, therapeutics that act to
express or restore CFTR have begun to emerge. A
remarkable diversity of these therapeutics is evident with
regard to their mechanisms of action (Fig. 1) and, as discussed here, a number of them are beginning to demonstrate efficacy in trials or in the clinic.
2.1 Small-Molecule Therapies for Improving CF
Transmembrane Regulator (CFTR) Function
In excess of 2000 variants of the CFTR gene have been
described [23], with the consequence of each for the fate of
the protein falling into one of six classes (Fig. 2) [24, 25].
The first class results in CFTR simply being absent from
the cell by virtue of deletion of all or part of the gene, a
premature stop codon being introduced into the gene, a
frame-shifted gene or one which produces alternately
spliced messenger RNA (mRNA). The second class of
mutations comprise those that generate a protein incapable
of being trafficked to the membrane. Such misfolded proteins are targeted for proteosomal degradation or remain in
a partially mature state in the cytoplasm or endoplasmic
reticulum. It is in this class that the common mutant,
p.Phe508del CFTR, lies.
Substitutions of amino acids in either nucleotide-binding
domain may yield a protein of sufficient structural normalcy that it is trafficked to the membrane. However, such
mutations may result in a third class of defective proteins,
so-called gating mutants, whereby the chloride transport
capability of the protein is greatly reduced. Alternately, if it
possesses one of the fourth class of mutations, then an
incorrect amino acid in one of the membrane spanning
domains can alter the transmembrane pore sufficiently to
prevent conductance of chloride (or bicarbonate).
Normal physiological function requires not only native
CFTR but also sufficient levels of the protein. The fifth
class of mutations comprise those that result in the degradation of some proportion of the mRNA, thus reducing the
quantity of CFTR produced. Similarly, the sixth class of
mutations give rise to CFTR that is recycled from the
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Fig. 1 Prominent examples of
the broad array of therapeutic
strategies that are showing
promise for the instigation of
normal expression and function
of cystic fibrosis transmembrane
regulator (CFTR), and their
cellular targets. Ata ataluren,
GP67a-pDNA lipid-enclosed
DNA plasmid, Iva ivacaftor,
Lum lumacaftor, ZFN zinc
finger nuclease
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Fig. 2 Overview of the classes of defect into which mutant variants of cystic fibrosis transmembrane regulator (CFTR) may be categorised,
grouped according to which of the prominent chemotherapeutic agents are designed to compensate for said defect. mRNA messenger RNA

plasma membrane with a frequency that cannot sustain
normal levels of chloride throughput.
The first class of mutations that may afflict the CFTR
gene include those that result in the inclusion of a premature termination codon (PTC) in the sequence. This will, in
most cases, cause the degradation of the PTC-containing

mRNA or the truncated protein translated from it. Smallmolecule therapeutics have been developed that can induce
the read-through of the aberrant mRNA as normal [26].
Assuming that the PTC did not accompany a frameshift of
the ensuing mRNA sequence, a protein of potential normalcy may be translated; the utility of such therapeutics
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extends to improving the likelihood of the correct peptidyltransfer RNA binding at the A site of the ribosome while
the PTC is present, overcoming the potentially deleterious
effect of the absence of an amino acid which the PTC
would otherwise cause.
One of the furthest-progressed PTC correctors in
development is PTC124 (generic name ataluren), being
brought to market by PTC Therapeutics (South Plainfield,
NJ, USA). It has advantageous potency and tolerability
relative to small molecules of comparable function and has
been shown to have encouraging efficacy in patients
amenable to treatment [27]. In assessing its physiological
effect in people with CF harbouring a class I mutation on at
least one allele, two open-label clinical trials demonstrated
an effect on nasal potential difference—a metric of CFTR
function—in the majority of patients over the durations of
study (Table 1) [28, 29]. No change in percentage FEV1
was apparent, though this was unsurprising given treatment
extended for only 6 weeks.
Ataluren has recently been subject to a randomised
controlled phase III trial in 238 patients who received the
drug for 48 weeks [30], with the primary outcome of the
study being lessening of the rate of decline of FEV1. Those
patients receiving treatment experienced a marginally lesser decline in FEV1 with respect to the control group
(2.5 % decline vs. 5.5 % decline; P = 0.12; Table 1). The
results of the study do not seem immediately impressive;
however, the ability of the drug to preserve patients’ lung
function over an extended period of time (years or decades)
would be a more informative and useful metric and a
halving of the rate of decline over 1 year, as this study
demonstrated, is encouraging.
Moreover, post hoc subgroup analysis demonstrated that
those patients who had received ataluren, but who were not
concurrently taking aminoglycoside antibacterials demonstrated significantly less decline in FEV1 with respect to
their counterparts who had received placebo (0.7 vs. 6.4 %;
n = 44, P = 0.0082). This subgroup benefit likely stems
from the mechanism of aminoglycoside action in which
such compounds bind to ribosomal RNA [31]. Here, it may
interfere with the ability of ataluren to effect readthrough
of PTC-harbouring CFTR mRNA, positing discontinuation
of aminoglycoside treatment as an indication for positive
response to ataluren. This hypothesis is presently under
investigation in the form of a repeat study of the aforementioned phase III trial specifically recruiting patients
who are not undergoing treatment with aminoglycoside
antibacterials [120].
For the majority of mutations, CFTR protein is produced, albeit in a non-functional form. This has provided
the opportunity for development of therapeutics that can
restore the normal functioning of the protein. Broadly
speaking, such therapeutics fall into one of two categories:
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potentiators of CFTR open-conformation (enabling
throughput of greater quantities of chloride) and correctors
of CFTR structure (and, hence, function). Perhaps the most
prominent example of a therapeutic targeting the defective
CFTR itself is the small molecule, ivacaftor (brand name
KalydecoÒ), developed by Vertex Pharmaceuticals (Boston, MA, USA).
Ivacaftor was designed to potentiate the channel opening
of CFTR bearing a class III single-nucleotide polymorphism, Gly551Asp, and received US FDA approval for the
treatment of people with CF bearing this mutation—representing *5 % of patients—in 2012 [32]. It had demonstrated statistically significant therapeutic efficacy, with
respect to control subjects who continued standard treatment, in two randomised controlled phase III trials and a
subsequent open-label extension over 48 weeks and up to
144 weeks, respectively (Table 2) [33–35]. Each trial utilised the common primary endpoint of improvement or
lesser decline in FEV1. The drug not only halted decline in
FEV1 but improved it relative to the baseline established at
the trials’ outset, displaying an *10 % improvement in
FEV1 [36].
Given its efficacy when administered to patients
homozygous for the Gly551Asp mutation, ivacaftor was
then trialled in patients homozygous for Phe508del; however, it failed to demonstrate a significant change in FEV1
relative to control subjects [37], reflecting the difference in
the nature of the defect affecting CFTR. Nonetheless,
ivacaftor treatment appears to be a potent and efficacious
therapy for adults with CF who harbour homozygous
Gly551Asp mutant CFTR alleles; it improves FEV1 and
weight gain as well as reducing incidence of infection by
Pseudomonas aeruginosa and prolonging intervals
between pulmonary exacerbations [38]. The drugs’ efficacy
in patients who have other class III mutations has also been
demonstrated clinically [39], leading to its approval as a
treatment in patients harbouring such mutations, as well as
in patients with p.Arg117His CFTR [32]. It may also prove
useful for patients who have other ‘partial function’
mutations (classes III–V), further extending its reach.
Moreover, lesser doses are being trialled in paediatric
patients to assess tolerability, as CF pathology is often
apparent in infancy [40, 41]; ivacaftor treatment is presently approved to commence from 2 years of age [32].
While the requirement for early intervention is apparent,
this is accompanied by several caveats. As mentioned,
tolerability is an issue, given the load placed particularly on
the hepatic cytochrome, cytochrome P450 3A (CYP3A), by
ivacaftor [40]. In addition, the yearly cost per patient of
ivacaftor treatment is considerable—£182,000 per patient
per year in the UK—leading to stringent assessment of its
clinical benefit [42, 43], which may limit the breadth of
patients to whom it will be administered.

12 (6–18)

Ataluren 10 mg/kg
morning, 10 mg/kg
afternoon and 20 mg/kg
evening per day for
14 days

Ataluren 4 mg/kg morning,
4 mg/kg afternoon and
8 mg/kg evening per day
for 14 days

Ataluren 10 mg/kg
morning, 10 mg/kg
afternoon and 20 mg/kg
evening per day for
14 days

Ataluren 4 mg/kg morning,
4 mg/kg afternoon and
8 mg/kg evening per day
for 14 days

Matching placebo

Ataluren 10 mg/kg
morning, 10 mg/kg
midday and 20 mg/kg
evening

Treatment regimen

90 (40–103)

65 (41–117)

60.2 (36.2–92.6)

62.1 (38.4–90.3)

% FEV1 at
baseline (range)

6d

6b

48

Study
duration,
weeks

–e

–c

0

0

40 [-6.4 (12.6)]

P = 0.0082

P = 0.12

-5.5 (12.56)

38 [-0.7 (11.9)]

No. of patients undergoing
aminoglycoside treatment
[change in % FEV1 (SD)]

-2.5a (13.3)

Change in %
FEV1 (SD)

e

d

c

b

a

Reported as ‘‘no statistically significant change’’

Cohorts received treatment for 14 days and, following a 14-day washout period, received the other treatment listed

Figure 5 in original report, no apparent difference day 0 vs. day 42

Relative change with respect to baseline
Inclusive of 14-day washout period between treatment cycles

CFTR cystic fibrosis transmembrane regulator, FEV1 forced airway expiratory volume in 1 s, RCT randomised controlled trial, SD standard deviation

14

14

Open-label
crossover Study

25 (18–56)

23.2 (8–53)

103 (50)

23 (52)

22.8 (6–49)

Median age,
years (range)

100 (48)

No. of patients
completing (% female)

Single-arm,
open-label study

Other

Dual-arm RCT

Phase III

Study type

[29]

[28]

[30]

References

Table 1 Selected data reported from clinical trials of ataluren administration in people with cystic fibrosis harbouring a class I mutation in the CFTR gene on at least one allele. Percentage
predicted FEV1 is reported at baseline and following treatment for both those in receipt of medication and control subjects who had received placebo treatment, where applicable
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25 (12–39)
16.6 (8–43)

28 (43)
20 (50)

Dual-arm RCT

Dual-arm RCTcrossover with OLE
Observational study

27.7 [9.8]
26.0 [9.6]
9.8 [1.9]
9.8 [1.8]
21.7 (6–47)
21.1 [11.4]

77A (53)
67B (52)
26C (65)
22D (41)
19i (52.6)

151 (46)

32.7 [17.4]

35 (57)

Dual-arm RCT

Other
OLEg

8.9 (6–11)f
29.2 [16.6]

26 (38)
34 (56)

150 mg once
daily

150 mg/12 h

150 mg/12 h

Placebo/12 h

Placebo/12 h
150 mg/12 h

8.9 (6–11)f

26 (65)

Placebo once
daily
150 mg/12 h

24.7 (12–53)

78 (51)

150 mg once
daily

26.2 (12–53)

83 (53)

Dual-arm RCT

Phase III
Dual-arm RCT

Placebo/12 h
Ivacaftor
150 mg/
12 h
Placebo/12 h

Placebo/12 h
150 mg/12 h

24a (18–42)
22.8 (12–52)

4 (25)
112 (48)

Dual-arm RCT–
crossoverd

150 mg/12 h

Treatment
regimen

23a (18–40)

Mean age, years
(range) [SD]

8 (62)

No. of patients
enrolled (% female)

Phase II
Dual-arm RCT

Study type

[18.5]
[18.7]
[14.5]
[17.4]
(42.9–104.1)

82.6 [25.6]

71.9
62.2
94.9
83.6
79.1

75.7 [19.3]

83.7 (44.0–116.3)
70.2 [18.9]

84.7 (52.4–133.8)

63.7 (31.6–97.1)

63.5 (37.3–98.2)

74.8 (43–127)
97.2 [9.7]

77 (42–122)
79.7 (40–129)

65 (53–112)

Mean % FEV1 at
baseline (range) [SD]

26

24

144B

24

24

48e

4

16

4

Treatment
duration, weeks

6.7 (4.9–8.5)
P \ 0.001

9.4 [10.8]
9.5 [11.2]
10.3 [12.4]
10.5 [11.5]
13.5 (–6.9 to 36.5)

12.6 (6.6–18.3)c
P \ 0.001
0.1
2.6 [1.2]
P = 0.2
0.5 [1.1]

10.4 (8.6–12.6)c
P \ 0.0001
-0.2

–0.213

8.7b (2.3–31.3)
P = 0.56
7.3b (5.2–8.2)
1.5 (–0.6 to 4.1)c
P = 0.15
–0.213
7.1 (1.8–12.2)c
P = 0.0117

Mean absolute change in
% FEV1 (95 % CI) [SD]

Non-Gly551Asp
gating mutation
Gly551Asp, C1
allele

Gly551Asp, C1
allele

Arg117His, C1
allele

Gly551Asp, C1
allele

Gly551Asp, C1
allele

Gly551Asp, C1
allele

Phe508del
homozygous

Gly551Asp, C1
allele

CFTR genotype

KONNECTION;
[39]
GOAL; [38]

PERSIST; [35]

KONDUCT;
[122]

ENVISION; [34]

STRIVE; [33]

[121]

DISCOVER;
[37]

[75]

References

Table 2 Selected data reported from clinical trials of ivacaftor administration to people with cystic fibrosis heterozygous or homozygous for alleles giving rise to a gating mutation in CFTR.
Percentage predicted FEV1 is reported at baseline and following treatment for both those in receipt of medication and control subjects who had received placebo treatment, where applicable

6
M. P. Murphy, E. Caraher

30.3 [7.5]
None
23 (21–27)j
35 (49)

CFTR cystic fibrosis transmembrane regulator, CI confidence interval, FEV1 forced airway expiratory volume in 1 s, OLE open-label extension, RCT randomised controlled trial, SD standard deviation
a
Median
b
Relative change with respect to baseline
c
95 % confidence interval for difference between arms
d
Cohort data are collated
e
Primary endpoint considered at 24 weeks
f
Limits: 6–11 years
g
Previous cohort: A STRIVE–ivacaftor; B STRIVE–placebo; C ENVISION–ivacaftor; D ENVISION–placebo
h
Duration is inclusive of previous enrolment in STRIVE or ENVISION
i
Patients who received ivacaftor consecutively during treatment legs
j
Median (interquartile range)
k
Median follow-up

Non-Gly551Asp

[123]
Gly551Asp, C1
allele

3.8 (0.2–7.7)j
P = 0.009
0.6 (–2.1 to 2.8)j
38k
26.5 [7.2]
150 mg once
daily
22 (20–31)j
21 (52)
Case–control study

Treatment
regimen
Study type

Table 2 continued

No. of patients
enrolled (% female)

Mean age, years
(range) [SD]

Mean % FEV1 at
baseline (range) [SD]

Treatment
duration, weeks

Mean absolute change in
% FEV1 (95 % CI) [SD]

CFTR genotype

References
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Concern over the costings of new investigational drugs
for ostensibly orphan conditions may be tempered somewhat by the nature of the re-distribution of revenue. The
arrangement in place between Vertex Pharmaceuticals and
the Cystic Fibrosis Foundation—the US-based not-forprofit CF research organisation, whose model of venture
philanthropy has seen it receive *US$3.3 billion in drug
royalties in 2014 [44]—may help to ensure continued high
levels of research into the condition.
Vertex Pharmaceuticals has also progressed to clinical
trials with a therapeutic, generic name lumacaftor,
designed to assist in the trafficking of Phe508del CFTR to
the epithelial membrane [45]. Despite in vitro mechanistic
evidence, phase II trials failed to show a benefit of taking
lumacaftor for patients homozygous for the Phe508del
mutation (Table 3) [46], which represents the genotype of
approximately 50 % of CF patients in both the EU and
USA [22]. Accordingly, it was decided to combine lumacaftor treatment with ivacaftor treatment on the basis that
ivacaftor may prove effective once Phe508del CFTR had
been trafficked. Phase II trials of several dosage permutations of this combined therapy showed a modest
improvement in FEV1 at high doses of each therapy:
600 mg of lumacaftor once daily and 250 mg of ivacaftor
once daily [47]. Patients in this treatment arm demonstrated a 5.6 % improvement in % FEV1, and, as such, this
regimen was progressed to two phase III trials which are
currently undergoing open-label extensions having compared 600 mg lumacaftor once daily vs placebo and
400 mg lumacaftor twice daily vs placebo, respectively
[48]. The aforementioned phase III trials each demonstrated significant improvement in percentage FEV1 and
other metrics (Table 3). Accordingly, licensing for a
combination therapy of lumacaftor and ivacaftor (trade
name OrkambiTM) has been approved by the FDA [49].
There are other novel therapeutics following in the
developmental pipeline of Vertex Pharmaceuticals, focused
on the major mutations in CF. The furthest progressed of
these is another corrector of Phe508del CFTR, designated
VX-661. This has shown an ability to improve CFTR
operation in vitro and seems to be well-tolerated in patients
with some efficacy when administered in conjunction with
ivacaftor [50].
The same defects are currently being targeted by other
companies or institutions. For example, Novartis have
developed a series of correctors for Phe508del CFTR that
possess similar functional activity to those of the Vertex
therapeutics [51]. Many other candidate chemical entities
have so far been declared to have efficacy in restoring
CFTR function in vitro and, undoubtedly, further useful
therapies will emerge during clinical trials [36].
The current high cost of the ivacaftor regimen had raised
doubts as to whether it would be supported by public health

25.5 [6.7]

30.8 [12.4]

11 (45)

17

Placebo once
daily ? placebo/12 h

Lumacaftor 400 mg/
12 h ? ivacaftor 250 mg/
12 h

Lumacaftor 600 mg once
daily ? ivacaftor
250 mg/12 h

Lumacaftor 400 mg once
daily ? ivacaftor
250 mg/12 h

Lumacaftor 600 mg once
daily ? ivacaftor
250 mg/12 h

26.7 [6.5]

21 (52)

27.5 [7.2]

29.2 [8.5]

21 (43)

Lumacaftor 200 mg once
daily ? ivacaftor
250 mg/12 h

21 (38)

28.1 [9.0]

23 (48)

Placebo once
daily ? placebo/12 h

Placebo once
daily ? placebo/12 h

30.1 [10.3]

21 (48)

Lumacaftor 200 mg once
daily ? ivacaftor
250 mg/12 h
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28.6 [9.1]

21 (62)

Lumacaftor 200 mg once
daily ? ivacaftor
150 mg/12 h

Placebo/12 h ? placebo/
12 h

28.5 [9.8]

20 (40)

Phase II RCT,
multiple armsa

Treatment regimen

4

Mean age, years
(range) [SD]

No. of patients
enrolled (% female)

Study type

68.5 (38.3–101.7)

72.0 (36.4–107.1)

63.7 (41.8–93.4)

65.6 (37.0–98.4)

67.4 (40.4–91.1)

72.4 (43.3–99.1)

69.1 (32.8–100.8)

57.0 (39.1–93.3)

75.1 (42.4–117.1)

% FEV1 at
baseline (range)

4

4

4

4

4

4

1

1

1

Treatment
duration, weeks

P = 0.067

2.3 (-0.8 to 5.4)

-1.6 (-4.2 to 1.1)

P = 0.003

6.1 (2.0–10.2)

P \ 0.001

6.2 (3.3–9.0)

P = 0.074

2.0 (-0.9 to 4.8)

P = 0.072

2.0 (-0.8 to 4.8)

0.3 (-2.6 to 3.1)

P = 0.908

0.5 (-2.8 to 3.8)

P = 0.176

3.1 (0.1–6.1)

Mean absolute change in
% FEV1 (95 % CI)

Heterozygous

Heterozygous

Homozygous

Homozygous

Homozygous

Homozygous

Homozygous

Homozygous

Homozygous

Homozygous

Homozygous

Phe508del
status
[47]

References

Table 3 Selected data reported from clinical trials of lumacaftor administration to people with cystic fibrosis homozygous or heterozygous for the c.1521_1523delCTT CFTR allele which
gives rise to mistrafficked p.Phe508del CFTR. The percentage predicted FEV1 is reported at baseline and following treatment for both those in receipt of medication and control subjects who
had received placebo treatment, where applicable
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schemes or insurance providers. However, given the larger
cohort of patients eligible to receive OrkambiTM, the latter
regimen has been offered at a cost lower than that for the
ivacaftor monotherapy [52], which may facilitate its prescription to patients. Longer term, however, a proliferation
of personalised medicines for CF seems unsustainable from
an economic standpoint and there are numerous calls for
action to be taken to ensure that costs are controlled, while
preserving research investment [43, 53].

Difference in percentage change in % FEV1 from baseline with respect to placebo
c

Reported here as pooled data arising from TRAFFIC and TRANSPORT studies

2.2 Gene Therapy for the Restoration of Normal
CFTR Function

b

CFTR cystic fibrosis transmembrane regulator, CI confidence interval, FEV1 forced airway expiratory volume in 1 s, NA not applicable, RCT randomised controlled trial, SD standard deviation
All patients had received the indicated dose of lumacaftor or placebo for 14 days (group 1–3) or 28 days (all other groups) immediately prior to commencing dual treatment

60.4 (33.9–99.8)
25.4 (12–64)
371 (48.8)

Placebo/12 h

60.5 (31.3–96.5)
Lumacaftor 400 mg/
12 h ? ivacaftor 250 mg/
12 h
24.5 (12–57)
369 (49.5)

a

NA

P \ 0.001

4.8 (3.0–6.6)c

Traffic and
Transport;
[48]
Homozygous
P \ 0.001

25.3 (12–54)
368 (49.3)
Phase III triplearm RCTb

Lumacaftor 600 mg once
daily ? ivacaftor
250 mg/12 h

60.8 (31.1–92.3)

24

5.6 (3.8–7.3)c

References
No. of patients
enrolled (% female)
Study type

Table 3 continued

Mean age, years
(range) [SD]

Treatment regimen

% FEV1 at
baseline (range)

Treatment
duration, weeks

Mean absolute change in
% FEV1 (95 % CI)

Phe508del
status

Current and Emerging Therapies for the Treatment of CF or Its Symptoms

While antibacterial use is frequent in clinical treatment of
CF, arguably the most direct route to treating CF, as well as
CFTR-related diseases, would be to integrate the native
gene into airway stem cells in vivo. Such integrating vectors exist [54] but have been demonstrated to be oncogenic
in some settings, justifiably giving rise to concerns over the
use of integrating gene therapy [55]. The next best option
would be to introduce copies of the native CFTR gene into
the cells of the affected epithelia. Encouraging work has
been carried out in vitro in this regard. Introduction of the
native CFTR gene into CFTR-deficient airway epithelial
cell line cells—via a transformed human parainfluenza
virus—has been shown to result in the expression of the
protein in those cells [56]. Furthermore, that study highlighted that normal ASL height was restored above the cell
layer following induction of expression in as few as 25 %
of the cells, lessening the issues of bioavailability and
transfection efficiency of the vector.
The utility of virally mediated gene delivery has
potential issues of toxicity or interference with cell functioning derived from the virus’ actions. These problems
were encountered during efforts to use respiratory adenoviruses as delivery vectors; while they possessed a natural
ability to traverse the airway epithelium, immune responses
curtailed the expression of adenoviral transgenes [57].
As such, design of a viral delivery vector should account
for these factors and further modifications to the virus, such
as rendering it more immunotolerable, may be necessary to
lessen its negative impact [58]. Even overcoming these
issues, the turnover of epithelial cells requires the repeated
administration of the vector throughout the life of the
patient, ultimately resulting in failure of the virus due to its
recognition and destruction by the immune system. This
would, in turn, place a burden on the development of these
viral vectors as they would require continual re-engineering and, hence, renewed regulatory approval.
Tolerance by the immune system for a given virus
would render it amenable to repeated administration, but a
virus possessing this property alongside an ability to infect
the airway epithelium, without adverse consequences, has
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not been described. This has, however, been overcome by
the generation of chimeric viruses possessing each of these
traits: the well-tolerated lentivirus, simian immunodeficiency virus, was transformed with coat proteins of the
respiratory infectious agent, Sendai virus, producing a virus
that possessed the favourable traits of both [59].
Given the complexities inherent in developing viruses as
vectors for gene therapy, alternate vectors for the delivery
of CFTR DNA are under investigation. For example, pHresponsive peptides may be used. These peptides are bound
to nucleic acids and remain so during endocytosis, subsequently enabling the escape of the nucleic acid from the
endosome through a pH-dependent conformational change
which disrupts the endosomal membrane [60]. Such a
delivery vector avoids much of the immunogenicity
inherent in a virus.
It should be noted that, while CF is a disease affecting
multiple organs, correction of defects in the airway will
provide a significant improvement in the quality of
patients’ lives as well as an extension of their lifespan and
has been pursued most extensively for this reason, in
conjunction with the supposed ease of delivery of therapies
via inhalation. However, the mucous layer presents an
obstacle to delivery of therapeutics in this setting. For
(relatively) small-molecule therapeutics, access to the
epithelium may be improved by coating them in a nonmucous-adhesive compound such as polyethylene glycol
(PEG), the efficacy of which can be further improved by
coadministration with a mucolytic agent such as N-acetyl
cysteine [61].
Combining a non-viral vector with each of these traits
would represent a promising gene therapy for the treatment
of CF lung disease. To that end, the UK CF Gene Therapy
Consortium have collectively progressed research into such

a vector. A plasmid harbouring CFTR was depleted of proinflammatory CpG motifs and encapsulated within a proprietary cationic lipid, GL67 (developed by Genzyme,
Cambridge, MA, USA), in conjunction with the neutral
lipid dioleoylphosphatidylethanolamine and a PEG-containing fusion lipid (Fig. 1). This has been shown in a
murine study to have a favourable tolerability and induce
persistent expression of CFTR, and each of these characteristics were maintained throughout the repeated-dose
study [62].
The outcome of this study gave rise to a phase IIb
clinical trial of the formulation. It was demonstrated that
administration of a once-monthly dose of the formulation
detailed above over 12 months arrested the decline in
FEV1 percentage for treated patients with respect to those
who had received nebulised saline as placebo (-0.4 vs. 4.0 %, respectively; Table 4) [63]. While modest in size, it
is notable that some treated patients had better responses
than others, which indicates that a study powered to
identify subgroup effects may lead to further improvement
in the utility of the therapy. Moreover, adverse events were
comparable to the placebo-treated cohort and response did
not depend on the type of CFTR mutation borne by patients
(with respect to Phe508del status).
Successful transfection of airway cells with the CFTR
gene subsequently requires it to be expressed. The plasmid
being utilised by the UK CF Gene Therapy Consortium
harbours a humanised promoter to ensure expression, but a
number of other groups have sought to correct the sequence
that already exists. The recent advent of genome editing
tools has made this feasible. One such tool, which has been
applied to the introduction of CFTR into the genome, is
zinc finger nuclease (ZFN) technology. This comprises a
fusion protein, one domain of which specifically recognises

Table 4 Selected data from prominent clinical trials of other interventions, curative or palliative, against cystic fibrosis lung disease
Study type

Phase II dualarm RCT

No. of patients
completing (%
female)

Mean age,
years (SD)

Treatment regimen

% FEV1 at
baseline (range)

Study
duration,
weeks

Mean response
(95 % CI)

References

62 (50)

23.6 (10.8)

pGM169/GL67A
5 mL/28 daysa

69.9 (49.6–89.9)

52

-0.4b (-2.8 to
2.1)

[63]

54 (46)

26 (13)

Placebo: 0.9 %
saline/28 days

334 (44.6)

21.3 (10.7)

Inhaled mannitol
400 mg twice daily

63.6 (25–105)

232 (49.8)

21.6 (10.5)

Inhaled mannitol
50 mg twice daily

61.9 (30–100)

P = 0.046

Phase III
dual-arm
RCT

-4.0b (-6.6 to
-1.4)

69 (49.6–89.9)
26

3.6c

[78]

NA

CI confidence interval, FEV1 forced airway expiratory volume in 1 s, NA not applicable, RCT randomised controlled trial, SD standard deviation
a

±5 days

b

Relative change with respect to baseline

c

Difference between groups in absolute % FEV1
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short (9–12 bp) sequences of DNA, while the other possesses non-specific endonuclease activity capable of
introducing double-strand breaks into the DNA at the targeted site, allowing the sequence of interest to insert [64].
Such ZFN complexes form heterodimers to carry out this
activity, enabling the recognition of *18 bp sequences,
hence providing a high degree of specificity [65]. This
approach has been demonstrated in vitro to correct the
defective CFTR sequence in epithelial cells having the
c.1521_1523delCTT genotype, which gives rise to the
Phe508del mutant CFTR [66].

3 Indirect Therapies for CF Management
3.1 Putative Mediators of Improved Lung
Physiology
Concurrent efforts are also ongoing to correct the defective
physiology evident in CF by compensating for the lack of
functional CFTR, a strategy that has the advantage of being
applicable to all patients with CF. Most directly, increasing
the activity of alternative chloride channels could, in
principle, restore the native phenotype of the mucosal
epithelium. For example, the calcium-activated chloride
channel, TMEM16A, is expressed on airway goblet cells
(which secrete mucins) and contributes to mucin release
[67]. Mouse ASL height is also regulated by TMEM16A
[68]. A direct-acting, long duration pharmacological
modulator of TMEM16A is currently being sought [69].
Alternatively, modulation of sodium absorption, which is
hyperactive in CF, may be considered [22]. The epithelial
sodium channel (ENaC) has been explored in this context,
with some therapeutics having reached clinical trials before
ultimately being rejected on the basis of lack of efficacy due
to insufficient potency or duration of effect or adverse effects
such as pulmonary oedema [70, 71]. Efforts in this regard are
continuing to pursue longer-acting modulators of ENaC,
with some demonstrating increased ASL height and
mucociliary clearance in animal models [72]. More recently,
however, additional regulators of ENaC have been described, offering targets for candidate drugs with more finely
tuned effects [73]. Similarly, the chaperones that guide the
folding and trafficking of CFTR itself have been proposed for
therapeutic action, which would be of particular benefit to
class II mutations that do not reach the plasma membrane
and class V mutations where CFTR is recycled from the
membrane too quickly [74].
Given the attractiveness of ostensibly curing a chronic,
debilitating, life-shortening condition, combined with the
apparent requirement to take the aforementioned therapeutics for the duration of life [75], there is considerable
research endeavour taking place into their further
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improvement. Presumably, the combined efforts of various
entities in this regard will eventually yield an effective,
persistent correctional treatment, but in the intervening
years palliative therapy remains the best available option.
One such therapy concerns emulating the effect of ASL
hydration, which is lacking in CF, by inducing osmosis of
water from the airway cells into the luminal space through
the inhalation of nebulised hyperosmolar solutions or dry
powders. Two such osmolytes are in use: hypertonic saline,
which overcomes ENaC-mediated hyper-absorption of
sodium, and mannitol, which also establishes an osmotic
driving force; both of which also induce coughing, thereby
helping to dislodge deposited mucous. In concentrations as
high as 6 %, hypertonic saline has been demonstrated to
improve lung function after 16 weeks of therapy [76];
extension of therapy to 48 weeks failed to confirm
improved lung function but did extend the duration
between pulmonary exacerbations [77], highlighting the
utility of clearing the lungs of deposited material. By
comparison, two recent phase III trials of inhaled mannitol
demonstrated improved lung function for up to 26 weeks
(the duration of the studies) and prolonged the interval
between exacerbations (Table 4) [78].
There is potential for incidental effects of mannitol
administration, with in vitro evidence suggesting that the
presence of mannitol can induce sensitivity to the
antibacterial tobramycin in P. aeruginosa biofilm persister
cells [79], presumably due to carbon source recognition by
the bacteria leading to their ‘awakening’. Similarly, mannitol may enhance adhesion by CF-associated Burkholderia
multivorans strains [80], illustrating a potential need for
concurrent antibacterial treatment with mannitol therapy.
Treatment with recombinant human deoxyribonuclease
(rhDNase), also known as dornase alfa or pulmozyme,
represents another measure commonly employed to aid
breathing by clearance of pulmonary obstructions.
rhDNase treatment degrades the DNA derived from lysed
neutrophil infiltrates, enabling easier clearance by airway
clearance techniques such as saline therapy or thoracic
agitation to induce coughing [81]. This treatment can
improve lung function, though its efficacy in reducing
exacerbations is less clear [82]. It may also be useful for
disruption of microbial biofilms in the airways [83].
Given that lung damage driven by inflammation is the
major contributor to mortality in people with CF, inhaled
corticosteroids are often prescribed to lessen the extent of
inflammation experienced by patients. Oral prednisone had
been tested under clinical trials, lasting up to 48 months,
and has shown improvements in patients’ lung function
[84, 85]. However, an increase in adverse events compared
with the placebo group was evident and age-matched
growth impairment was noted among males for up to
several years following discontinuation of treatment [86].
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A recent systematic review of trials of inhaled corticosteroids (n = 13) failed to find a significant improvement in patients’ health while participating in those studies
[87]. The authors noted that withdrawal from corticosteroids often took place without issue and highlighted
possible negative side effects from taking them, in a parallel to the experience with oral prednisone. As a counterargument to the lack of trial evidence, such trials were
conducted for only a limited period of time in patients who
have already experienced prolonged inflammation. They
cannot reflect any benefit that early, prolonged intervention
with corticosteroids may have.
Improvement of patient health can not only enable better
outcomes to treatment and immunity to exacerbations but
can improve the quality of patients’ lives. To that end,
pancreatic or hepatobiliary insufficiency are often compensated for by supplementation with digestive enzymes
and vitamins specific to the needs of the patient, alongside
maintenance of a high-calorie diet that emphasises high
intake of fat and protein [88].
PERT is widely used; porcine-derived pancrelipase has
demonstrated tolerability and mediates improvements to
absorption of fats and nitrogenous compounds, hence
contributing to restoration of normal growth and maintenance of adequate weight [89]. Porcine-derived native
enzymes do, however, present challenges regarding dosage
and efficacy during gastrointestinal transit [90]. Accordingly, non-animal-derived PERT agents are being pursued
with liprotamase, for example, having demonstrated clinical efficacy and presently undergoing further investigation
[91, 92]. Similarly, microbially derived lipases may be
effective as PERT agents and are under clinical investigation [93]. Bile acids are also administered for those
patients experiencing CF liver disease, though their efficacy is questionable [94] and probably dependent on the
residual functioning of the liver among other factors such
as age at intervention [95].
3.2 Antimicrobial Agents
Strategically related to amelioration of inflammation is the
removal of its cause, namely the colonisation of patients’
lungs by microorganisms. Numerous species of microorganisms are frequently isolated from CF lung sputum
samples, most commonly P. aeruginosa, Staphylococcus
aureus, Haemophilus influenzae, as well as the fungal
pathogen Aspergillus fumigatus and members of the
Burkholderia cepacia complex of bacteria (Bcc), but a host
of others are also frequently detected by routine culture
including Stenotrophomonas maltophilia, non-tuberculous
mycobacteria, etc. [96, 97].
P. aeruginosa, for example, has a prevalence ranging
from 13 to 75 % of CF patients, depending on age and
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geographic location [96, 98]. Its prevalence increases
steadily with age (from *25 % at the onset of adolescence
to *75 % at adulthood in the US population), reflecting
the tendency for many patients to become chronically
colonised with a given strain with worsening airway conditions, often defined as greater than 50 % of their sputum
samples being culture positive over a 12-month period
[99]. A recent study in the USA indicated that as many as
48 % of people with CF become colonised with
P. aeruginosa by the age of 6 years (n = 3608) [100].
Concurrently, the rate of pulmonary exacerbations significantly increases in patients following acquisition [101].
The overall prevalence of P. aeruginosa is falling, as
evident in US patient registry data, which can be attributed
to the success of early and frequent intervention with
antibacterials such as inhaled tobramycin or aztreonam
[102, 103]. A number of trials have demonstrated the utility
of inhaled antibacterials for improving lung function and
lessening the rate of pulmonary exacerbations in patients
with long-term colonisation by P. aeruginosa [104].
Moreover, if treatment with antibacterials of proven efficacy is commenced soon after acquisition of the bacterium,
it is possible to effectively eradicate P. aeruginosa [103].
While many patients for whom P. aeruginosa is successfully eradicated following early intervention were
shown to sustain the absence of the bacterium for at least
5 years, many failed to demonstrate an improvement in
their rate of pulmonary exacerbation [105]. This may
suggest that other microorganisms then dominate, emphasising that effective antimicrobial regimens against a broad
range of CF-associated pathogens is needed. This presents
a challenge where microorganisms of low prevalence are
concerned, as trials of the efficacy of candidate therapies
may be under-powered.
Considering the example of colonisation by species of
Burkholderia bacteria, their multi-drug-resistant status has
precluded the instigation of a standard course of treatment.
This is brought into sharp relief by the failure of a recent
review, carried out by the Cochrane collaboration, to find
even a single eligible trial of effective interventions against
Bcc bacteria [106]. Clinical trials are also lacking interventions against the increasingly prevalent methicillin-resistant S. aureus (MRSA) [107], S. maltophilia [108] or
non-tuberculous mycobacteria [109].
Such endeavours are not trivial, however, as evidenced
by findings from systematic reviews of trials of antibacterial interventions against chronic P. aeruginosa colonisation. A recent review of trials of oral antibacterials for the
treatment of P. aeruginosa failed to find a notable improvement to either lung function or quality of life [110].
The authors highlighted both the subjectivity of quality-oflife assessments, as well as the differential response of
different patients to a given treatment (into which
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contribute myriad factors). This situation is echoed in a
review of studies of inhaled tobramycin for treatment of
chronic P. aeruginosa colonisation [102], in which the
ability to improve clinical condition in the majority of
patients was clear, but the failure of some patients to
respond confounded large-scale analyses of antibacterial
efficacy.
In a more general sense, the preferential route of
antibacterial administration has proven equally difficult to
confirm, with none of oral, intravenous or nebulised
administration emerging as clearly more efficacious in
treating pulmonary exacerbations [111]. However, for
long-term therapy, inhalation may have an advantage,
particularly in the case of inhaled tobramycin [112, 113]. It
is also recognised that the propensity of successful
colonisers to form biofilms may necessitate the administration of types and concentrations of antibacterials with
anti-biofilm efficacy, though solid confirmation of this has
not yet been provided [114].
Hence, treatment decisions are informed by prior
experience and case reports. In the case of Burkholderia
bacteria, there are isolated case studies of successful
eradication of Burkholderia from CF patients and from
settings other than CF, such as successful intervention with
aztreonam in non-CF bronchiectasis [115]. However, while
early eradication is often attempted, using combined
intravenous and nebulised antibacterials, the success rate is
low, with many infections remaining in situ [116].
3.3 Transplant
Management of the CF pulmonary physiology and microbiome is a matter of delaying the decline in lung function,
but inevitably patients are rendered unable to achieve
sufficient oxygen intake through breathing and, as they
approach this point, bilateral lung transplantation is considered. In a retrospective study of 101 transplantations in
CF patients in Italy, the 1-, 5- and 10-year survival rates for
patients post-transplantation were 79, 58 and 42 %,
respectively, while FEV1 increased from a pre-operative
mean of 22 to 85 % 1 year after the operation [117].
Interestingly, these figures match those of a UK cohort of
transplant recipients, with mean FEV1 for those patients
improving from 21 to 78 % at 1 year, while survival rates
were 82 % at 1 year, 62 % at 5 years and 51 % at 10 years
(n = 176) [118].
Hence, there is a substantial survival and life-quality
advantage to be gained through transplantation. Although
there was sizable post-operative mortality (14.8 % of
patients in the Italian clinic), the potential benefits may be
decisive in listing patients for transplant. Supplementary to
this, many clinics view colonisation by certain bacteria,
such as Burkholderia, as a contra-indication for
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transplantation. In a UK CF clinic, *10 % of CF patients
who underwent lung transplantation had colonising
Burkholderia. Of these, *40 % died within a year following the operation, with the most frequent cause of death
being sepsis [119]. This greatly exceeded the mortality rate
for patients who did not harbour these bacteria, and these
outcomes led to that clinic ceasing to list CF patients who
harbour Burkholderia for transplantation.

4 Concluding Remarks
CF causes chronic morbidity in multiple organs, leading to
a substantial reduction in the lifespan of those affected.
Loss of lung function, mediated by tissue destruction pursuant to microbial colonisation and the attendant inflammatory response, is the most pronounced driver of
mortality for people with CF. As such, multiple avenues of
therapeutic interventions are being pursued. Ultimately,
restoration of the airways to a normal phenotype holds the
most promise for meaningful extensions of survival for
people with CF, whether by allowing the epithelium to
produce normal CFTR or by restoring the normal function
of existing CFTR. In the meantime, diminishing the
microbial burden in the airways is an important focus of
research, but requires potent antibacterials and better
delivery of them. These interventions are greatly aided by a
therapeutic strategy that addresses as many of the symptoms of CF as possible; the resulting improvements to
organ function and, hence, quality of life are instrumental
in continuing to extend the lives of people with CF.
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Máiz L, Giron RM, Olveira C, Quintana E, Lamas A, Pastor D,
et al. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic
fibrosis: systematic review of randomised controlled trials.
Expert Opin Pharmacother. 2013;14:1135–49.
Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Cochrane Database Syst Rev. 2014;11:CD004197.
Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower
airway infections. Ann Am Thorac Soc. 2014;11:425–34.
Mayer-Hamblett N, Kloster M, Rosenfeld M, Gibson RL,
Retsch-Bogart GZ, Emerson J, et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long-term
outcomes in cystic fibrosis. Clin Infect Dis. 2015;61:707–15.
Regan KH, Bhatt J. Eradication therapy for Burkholderia
cepacia complex in people with cystic fibrosis. Cochrane
Database Syst Rev. 2014;10:CD009876.
Lo DK, Hurley MN, Muhlebach MS, Smyth AR. Interventions
for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. Cochrane Database
Syst Rev. 2013;2:CD009650.
Amin R, Waters V. Antibiotic treatment for Stenotrophomonas
maltophilia in people with cystic fibrosis. Cochrane Database
Syst Rev. 2012;5:CD009249.
Waters V, Ratjen F. Antibiotic treatment for nontuberculous
mycobacteria lung infection in people with cystic fibrosis.
Cochrane Database Syst Rev. 2012;12:CD010004.
Remmington T, Jahnke N, Harkensee C. Oral anti-pseudomonal
antibiotics for cystic fibrosis. Cochrane Database Syst Rev.
2013;10:CD005405.
Ryan G, Jahnke N, Remmington T. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database Syst
Rev. 2012;12:CD008319.
Ryan G, Singh M, Dwan K. Inhaled antibiotics for long-term
therapy in cystic fibrosis. Cochrane Database Syst Rev.
2011;(3):CD001021.

Current and Emerging Therapies for the Treatment of CF or Its Symptoms
113. Das RR, Kabra SK, Singh M. Treatment of Pseudomonas and
Staphylococcus bronchopulmonary infection in patients with
cystic fibrosis. ScientificWorldJournal. 2013;2013:645653.
114. Waters V, Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Cochrane Database Syst Rev. 2012;11:CD009528.
115. Iglesias A, Artiles I, Cabanillas JJ, Alvarez-Sala R, Prados C.
Eradication of Burkholderia cepacia using inhaled aztreonam
lysine in two patients with bronchiectasis. Case Rep Pulmonol.
2014;192146.
116. Horsley A, Webb K, Bright-Thomas R, Govan J, Jones A. Can
early Burkholderia cepacia complex infection in cystic fibrosis
be eradicated with antibiotic therapy? Front Cell Infect Microbiol. 2011;1:18.
117. Diso D, Anile M, Patella M, Pecoraro Y, Rendina EA, Carillo C,
et al. Lung transplantation for cystic fibrosis: outcome of 101 single-center consecutive patients. Transplant Proc. 2013;45:346–8.
118. Meachery G, De Soyza A, Nicholson A, Parry G, Hasan A,
Tocewicz K, et al. Outcomes of lung transplantation for cystic
fibrosis in a large UK cohort. Thorax. 2008;63:725–31.
119. De Soyza A, Meachery G, Hester KL, Nicholson A, Parry G,
Tocewicz K, et al. Lung transplantation for patients with cystic

120.

121.

122.

123.

17
fibrosis and Burkholderia cepacia complex infection: a singlecenter experience. J Heart Lung Transplant. 2010;29:1395–404.
PTC Therapeutics. Study of ataluren in nonsense mutation cystic
fibrosis (ACT CF) [ClinicalTrials.gov identifier NCT02139306].
US National Institutes of Health, ClinicalTrials.gov. https://
clinicaltrials.gov. Accessed 15 Dec 2015.
Davies J, Sheridan H, Bell N, Cunningham S, Davis SD, Elborn
JS, et al. Assessment of clinical response to ivacaftor with lung
clearance index in cystic fibrosis patients with a G551D-CFTR
mutation and preserved spirometry: a randomised controlled
trial. Lancet Respir Med. 2013;1:630–8.
Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley
SA, et al. Efficacy and safety of ivacaftor in patients with cystic
fibrosis who have an Arg117His-CFTR mutation: a doubleblind, randomised controlled trial. Lancet Respir Med.2015;3:
524-33.
Barry PJ, Plant BJ, Nair A, Bicknell S, Simmonds NJ, Bell NJ,
et al. Effects of ivacaftor in patients with cystic fibrosis who
carry the G551D mutation and have severe lung disease. Chest.
2014;146:152-8.

